Development and Clinical Validation of Key Technologies for Non-invasive Breath Metabolic Fingerprinting for Large-scale Population Lipid Screening

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing Anzhen Hospital

About this trial

This study collects exhaled breath condensate samples from healthy populations and hyperlipidemic populations, analyzes the characteristics of the exhaled metabolic lipid profile for early identification of people with abnormal blood lipids, verifies the feasibility and accuracy of a new gas detection method for screening abnormal blood lipids, and explores a simple, fast, and non-invasive method for screening abnormal blood lipids.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Voluntarily sign the informed consent form

Disqualifiers

Patients with lung cancer, asthma, chronic obstructive pulmonary disease, cystic fibrosis, or acute respiratory distress syndrome

Women during pregnancy or breastfeeding

Patients with chronic kidney disease (GFR <60 ml/min) or liver cirrhosis

Individuals unable to cooperate in collecting exhaled breath samples

Trial design

Treatments tested in this trial

  • Lipid Abnormality Mass Spectrometry Screening Model

Treatment groups

280 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators